Literature DB >> 11943731

DNA mismatch repair deficiency accelerates endometrial tumorigenesis in Pten heterozygous mice.

Hong Wang1, Wayne Douglas, Marie Lia, Winfried Edelmann, Raju Kucherlapati, Katrina Podsypanina, Ramon Parsons, Lora Hedrick Ellenson.   

Abstract

PTEN mutation and microsatellite instability are two of the most common genetic alterations in uterine endometrioid carcinoma. Furthermore, previous studies have suggested an association between the two alterations, however the basis and consequence of the association is not understood. Recently it has been shown that 100% of female Pten(+/-) mice develop complex atypical hyperplasia by 32 weeks of age that progresses to endometrial carcinoma in approximately 20 to 25% of mice at 40 weeks. In an attempt to expand this mouse model of endometrial tumorigenesis and to further our understanding of the association betweenPten mutations and DNA mismatch repair deficiency, we generated Ptenheterozygous, Mlh1-null (mismatch repair deficient) mice. Significantly, the majority ofPten(+/-)/Mlh1(-/-)mice developed polypoid lesions in the endometrium at 6 to 9 weeks of age. By 14 to 18 weeks, all of the double-mutant mice had lesions histologically similar to those seen inPten(+/-) mice, and two of them exhibited invasive disease. Moreover, the frequency of loss of the wild-type Pten allele in the double-mutant mice at 14 to 18 weeks was similar to that seen in lesions from 40-week-old Pten(+/-) mice. Taken together, our results indicate that DNA mismatch repair deficiency can accelerate endometrial tumorigenesis inPten heterozygous mice and suggests that loss of the wild-type Pten allele is involved in the development/progression of tumors in this setting.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11943731      PMCID: PMC1867211          DOI: 10.1016/S0002-9440(10)62573-4

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  31 in total

1.  PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics.

Authors:  J I Risinger; K Hayes; G L Maxwell; M E Carney; R K Dodge; J C Barrett; A Berchuck
Journal:  Clin Cancer Res       Date:  1998-12       Impact factor: 12.531

2.  PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies.

Authors:  P L Dahia; R C Aguiar; J Alberta; J B Kum; S Caron; H Sill; D J Marsh; J Ritz; A Freedman; C Stiles; C Eng
Journal:  Hum Mol Genet       Date:  1999-02       Impact factor: 6.150

3.  Tumorigenesis in Mlh1 and Mlh1/Apc1638N mutant mice.

Authors:  W Edelmann; K Yang; M Kuraguchi; J Heyer; M Lia; B Kneitz; K Fan; A M Brown; M Lipkin; R Kucherlapati
Journal:  Cancer Res       Date:  1999-03-15       Impact factor: 12.701

4.  Different mutator phenotypes in Mlh1- versus Pms2-deficient mice.

Authors:  X Yao; A B Buermeyer; L Narayanan; D Tran; S M Baker; T A Prolla; P M Glazer; R M Liskay; N Arnheim
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

Review 5.  Mouse models for colorectal cancer.

Authors:  J Heyer; K Yang; M Lipkin; W Edelmann; R Kucherlapati
Journal:  Oncogene       Date:  1999-09-20       Impact factor: 9.867

6.  PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway.

Authors:  H Sun; R Lesche; D M Li; J Liliental; H Zhang; J Gao; N Gavrilova; B Mueller; X Liu; H Wu
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

7.  hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis.

Authors:  M Esteller; L Catasus; X Matias-Guiu; G L Mutter; J Prat; S B Baylin; J G Herman
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

8.  Stepwise deletions of polyA sequences in mismatch repair-deficient colorectal cancers.

Authors:  C Blake; J L Tsao; A Wu; D Shibata
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

9.  Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems.

Authors:  K Podsypanina; L H Ellenson; A Nemes; J Gu; M Tamura; K M Yamada; C Cordon-Cardo; G Catoretti; P E Fisher; R Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

10.  Causes and consequences of microsatellite instability in endometrial carcinoma.

Authors:  C C Gurin; M G Federici; L Kang; J Boyd
Journal:  Cancer Res       Date:  1999-01-15       Impact factor: 12.701

View more
  33 in total

Review 1.  Mouse models of inherited cancer syndromes.

Authors:  Sohail Jahid; Steven Lipkin
Journal:  Hematol Oncol Clin North Am       Date:  2010-12       Impact factor: 3.722

2.  PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors.

Authors:  Hannah P Yang; Alan Meeker; Richard Guido; Marc J Gunter; Gloria S Huang; Patricia Luhn; Lori d'Ambrosio; Nicolas Wentzensen; Mark E Sherman
Journal:  Cancer Causes Control       Date:  2015-09-16       Impact factor: 2.506

Review 3.  Progesterone: the ultimate endometrial tumor suppressor.

Authors:  Shujie Yang; Kristina W Thiel; Kimberly K Leslie
Journal:  Trends Endocrinol Metab       Date:  2011-02-25       Impact factor: 12.015

4.  Single nucleotide polymorphisms of DNA mismatch repair genes MSH2 and MLH1 confer susceptibility to esophageal cancer.

Authors:  Ming-Zhong Sun; Hui-Xiang Ju; Zhong-Wei Zhou; Hao Jin; Rong Zhu
Journal:  Int J Clin Exp Med       Date:  2014-08-15

5.  Endometrial tumorigenesis in Pten(+/-) mice is independent of coexistence of estrogen and estrogen receptor α.

Authors:  Ayesha Joshi; Hong Wang; Gaofeng Jiang; Wayne Douglas; Joanna S Y Chan; Kenneth S Korach; Lora H Ellenson
Journal:  Am J Pathol       Date:  2012-04-13       Impact factor: 4.307

6.  Increased incidence of endometrioid tumors caused by aberrations in E-cadherin promoter of mismatch repair-deficient mice.

Authors:  Irina V Kovtun; Kimberly J Harris; Aminah Jatoi; Dragan Jevremovic
Journal:  Carcinogenesis       Date:  2011-05-05       Impact factor: 4.944

7.  Differential roles of telomere attrition in type I and II endometrial carcinogenesis.

Authors:  Esra A Akbay; Cristina M Contreras; Samanthi A Perera; James P Sullivan; Russell R Broaddus; John O Schorge; Raheela Ashfaq; Hossein Saboorian; Kwok-Kin Wong; Diego H Castrillon
Journal:  Am J Pathol       Date:  2008-07-03       Impact factor: 4.307

8.  Oviduct-specific glycoprotein is a molecular marker for invasion in endometrial tumorigenesis identified using a relevant mouse model.

Authors:  Hong Wang; Ayesha Joshi; Lori Iaconis; Garron J Solomon; Zhaoying Xiang; Harold G Verhage; Wayne Douglas; Brigitte M Ronnett; Lora Hedrick Ellenson
Journal:  Int J Cancer       Date:  2009-03-15       Impact factor: 7.396

9.  Estrogen regulates DNA methyltransferase 3B expression in Ishikawa endometrial adenocarcinoma cells.

Authors:  Min Cui; Zeqing Wen; Zhongli Yang; Ji Chen; Fei Wang
Journal:  Mol Biol Rep       Date:  2008-12-24       Impact factor: 2.316

10.  PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma.

Authors:  James V Lacey; George L Mutter; Brigitte M Ronnett; Olga B Ioffe; Máire A Duggan; Brenda B Rush; Andrew G Glass; Douglas A Richesson; Nilanjan Chatterjee; Bryan Langholz; Mark E Sherman
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.